؉ /H ؉ exchanger regulatory factor (NHERF)-1 is a PDZ domain-containing adaptor protein known to bind to various receptors, channels, cytoskeletal elements, and cytoplasmic signaling proteins. We report here that the phosphorylation state of NHERF-1 is profoundly regulated by the cell cycle: NHERF-1 in HeLa cells is hyperphosphorylated in mitosis phase and much less phosphorylated at other points of the cell cycle. This mitosis phase-dependent phosphorylation of NHERF-1 could be blocked by roscovitine, consistent with phosphorylation by cyclin-dependent kinases. In vitro studies with purified NHERF-1 fusion proteins and purified kinases revealed that NHERF-1 was robustly phosphorylated by the cyclin-dependent kinase Cdc2. In contrast, the NHERF-1 relative NHERF-2 was not phosphorylated at all by Cdc2. NHERF-1 possesses two serines 
Many cell-surface receptors and channels are directly coupled to intracellular signaling proteins through interactions with scaffolding or adaptor proteins. Most adaptor proteins contain a number of modular interaction domains to facilitate the associations of multiple target proteins (1) . One common example of such a module is the PDZ 1 domain. PDZ domains can associate with specific carboxyl-terminal motifs on target proteins, and many PDZ domains can also oligomerize with other PDZ domains to enhance the scaffolding or adaptor function of PDZ domain-containing proteins (2) . Na ϩ /H ϩ exchanger regulatory factor-1 (NHERF-1) is a PDZ domain-containing protein that was first identified as a cofactor necessary for regulation of Na ϩ /H ϩ exchanger-3 (NHE3) function by phosphorylation (3) . Subsequently, NHERF-1 was identified as a binding partner for the actin-associated ERM proteins (ezrin, radixin, moesin, and merlin) and thus is also known as the ERM-binding phosphoprotein of 50 kDa (EBP50) (4, 5) . A close relative of NHERF-1 has been identified and is known variously as SIP-1 (6), E3KARP (7), and NHERF-2 (8) . NHERF-1 and NHERF-2 share 52% identity and a conserved domain architecture, possessing two PDZ domains followed by a unique carboxyl-terminal region that mediates association with the ERM proteins (9) .
The PDZ domains of NHERF-1 and NHERF-2 specifically recognize the carboxyl-terminal motif (S/T)XL (8, 10, 11) and are known to associate with a small number of transmembrane proteins other than Na ϩ /H ϩ exchangers, including the ␤ 2 -adrenergic receptor (8, 10, 12) , the cystic fibrosis transmembrane conductance regulator (8, 11, (13) (14) (15) , the sodium bicarbonate cotransporter (16) , the platelet-derived growth factor receptor (17) , the B1 subunit of the H ϩ -ATPase (18) , the TRP4 calcium channel (19) , and the type IIa sodium phosphate cotransporter (20) . The NHERF proteins also bind via their PDZ domains to a variety of intracellular signaling proteins, including SRY (6), phospholipase C␤1/2 (19) , phospholipase C␤3 (21), GRK6A (22) , YAP65 (23) , TAZ (24) , and Epi64 (25) . Moreover, it has recently been shown that the PDZ domains of NHERF-1 can homo-oligomerize (17, 26 -28) and also hetero-oligomerize with the PDZ domains of NHERF-2 (28) .
Since the NHERF proteins have such a large number of binding partners, a primary question of interest is how these interactions might be regulated in a cellular environment. NHERF-1 is known to be phosphorylated in cells (4, 22, 29 -31) , 1 The abbreviations used are: PDZ, PSD-95/Discs-large/ZO-1 homology; NHERF, Na ϩ /H ϩ exchanger regulatory factor; NHE3, Na ϩ /H ϩ exchanger-3; ERM, ezrin, radixin, moesin, and merlin; EBP50, ezrinbinding phosphoprotein of 50 kDa; SIP-1, SRY-interacting protein-1; E3KARP, NHE3 kinase A regulatory protein; GRK, G protein-coupled receptor kinase; GST, glutathione S-transferase; MAGI, membraneassociated guanylate kinase-like protein with an inverted domain structure; HEK, human embryonic kidney; PAGE, polyacrylamide gel electrophoresis.
and Ser 289 has been identified as a major site of phosphorylation (22, 29, 31) . Although Ser 289 of NHERF-1 can be phosphorylated in vitro by several kinases, the kinase responsible for phosphorylation of this site in most cells seems to be GRK6A, which avidly associates with the NHERF PDZ domains through its carboxyl terminus and efficiently phosphorylates NHERF-1 at Ser 289 (22) . Mutation of Ser 289 to alanine, however, does not block all cellular phosphorylation of NHERF-1 (22, 29) , suggesting that there are other unidentified sites of phosphorylation on NHERF-1. Here, we report that the NHERF-1 phosphorylation state varies profoundly with the cell cycle. More specifically, we report that NHERF-1 is phosphorylated by the cyclin-dependent kinase Cdc2 at Ser 279 and Ser 301 and that this phosphorylation regulates NHERF-1 oligomerization and association with the peptidylprolyl isomerase Pin1.
EXPERIMENTAL PROCEDURES
Preparation of Plasmids and Fusion Proteins-Hexahistidine-and S-tagged NHERF fusion proteins, for both full-length NHERF-1 and NHERF-2 and for various NHERF truncations, were created via insertion of polymerase chain reaction products derived from a rabbit NHERF cDNA into pET-30A (Novagen), followed by expression and purification as previously described (8) . NHERF-1 point mutants S279A, S301A, S279A/S301A, S279D, S301D, and S279D/S301D were created by polymerase chain reaction amplification from the native rabbit NHERF cDNA using mutant sequence oligonucleotides; the point mutations at positions 279 and/or 301 were confirmed by ABI sequencing. The NHERF-1 point mutants were inserted into both the pET-30A and pGEX-4T1 vectors for expression as hexahistidine/Stagged and GST-tagged fusion proteins, respectively. GST-Pin1 fusion protein was prepared using the human Pin1 cDNA inserted into pGEX-4T1 as previously described (32) . GST-MAGI-WW was prepared via polymerase chain reaction from a DNA template kindly supplied by Jonathan Wood and Christopher Ross (Johns Hopkins University). The DNA sequence encoding for amino acids 1-355 of human MAGI-2 (encoding both of the MAGI-2 WW domains) was amplified and inserted into the vector pGEX-4T1 for expression as a GST-tagged fusion protein.
Cell Culture and Transfection-All tissue culture media and related reagents were purchased from Life Technologies, Inc. HEK-293, HeLa, and ES2 cells were maintained in complete medium (Dulbecco's modified Eagle's medium plus 10% fetal bovine serum and 1% penicillin/ streptomycin) in a 5% CO 2 incubator at 37°C. To express FLAG-and/or hemagglutinin-tagged versions of NHERF-1 or NHERF-1 mutants, 2 g of total DNA (in a modified version of the vector pBK-CMV from Stratagene) was mixed with LipofectAMINE (15 l) and Plus reagent (20 l) (Life Technologies, Inc.) and added to 5 ml of complete medium in 10-cm tissue cultures plates containing cells at ϳ50 -80% confluency. Following a 4-h incubation, the medium was removed, and 10 ml of fresh complete medium was added. After another 12-16 h, the medium was changed again, and the cells were harvested 24 h later.
HeLa cells were synchronized at the G 1 /S phase boundary using the thymidine-aphidicolin double block method as previously described (33) . Cells in S phase were obtained 3 h after release from the G 1 /S phase block. Mitosis and G 2 phase cells were obtained following a 14 -18 h treatment with nocodazole (50 ng/ml; Sigma) as previously described (34) . The cell cycle state of the cells harvested following these various protocols was confirmed using flow cytometry.
Western Blotting-Samples (5 g/lane) were run on 4 -20% SDSpolyacrylamide gels (Novex) for 1 h at 150 V and then transferred to nitrocellulose. The blots were blocked in blot buffer (2% nonfat dry milk, 0.1% Tween 20, 50 mM NaCl, and 10 mM HEPES, pH 7.4) for at least 30 min and then incubated with primary antibody in blot buffer for 1 h at room temperature. The blots were washed three times with 10 ml of blot buffer and incubated for 1 h at room temperature with a horseradish peroxidase-conjugated secondary antibody (Amersham Pharmacia Biotech) in blot buffer. Finally, the blots were washed three more times with 10 ml of blot buffer and visualized via enzyme-linked chemiluminescence using the ECL kit from Amersham Pharmacia Biotech.
Kinase Assays-In vitro phosphorylation experiments were carried out at room temperature in a final volume of 25 l with 10 mM HEPES, pH 7.4, 10 mM MgCl 2 , and 2 mM EDTA. In this buffer, purified fusion proteins, either His-NHERF-1 (2 g) or a mutant version of His-NHERF-1, were incubated with purified recombinant human Cdc2/ cyclin B (10 units; Calbiochem). Reactions were initiated via the addition of [␥-
32 P]ATP (1 Ci; Amersham Pharmacia Biotech) and were allowed to proceed for 30 min at room temperature before being stopped with SDS-PAGE sample buffer. Phosphorylated samples were run on 4 -20% SDS-polyacrylamide gels, fixed, dried, and exposed to film. The extent of phosphorylation was quantified by scanning of films and densitometric analysis of bands.
Plate Assays-GST-NHERF-1 and GST alone were expressed as described above and purified on glutathione-agarose beads (Sigma). The GST fusion proteins were then eluted from the beads using 250 mM reduced glutathione (Sigma) in harvest buffer (10 mM HEPES, 50 mM NaCl, 5 mM EDTA, and protease inhibitor mixture (Roche Molecular Biochemicals)). The excess glutathione was removed via multiple rounds of concentration and dilution with fresh harvest buffer. The eluted GST fusion proteins were used to coat the wells of 96-well high affinity binding dishes (Fisher). Each well was coated overnight at 4°C with 1 g of fusion protein in a 100-l final volume of harvest buffer. After the coating solution was removed, the wells were washed twice with harvest buffer and then blocked with blot buffer for 30 min at room temperature. His/S-tagged NHERF-1 fusion proteins diluted in blot buffer were added to the precoated wells at the indicated concentrations and incubated for 1 h at room temperature. The wells were then washed five times with 200 l of blot buffer. For detection, S protein-alkaline phosphatase conjugate (Novagen) diluted 1:4000 in blot buffer was added to the wells (100 l/well) and incubated for 1 h at room temperature. The wells were then washed four times with blot buffer and twice with harvest buffer. Following the final wash, each well was incubated with 100 l of alkaline phosphatase substrate (Bio-Rad), and the absorbance at 405 nm was determined using a Thermomax microplate reader (Molecular Devices) to provide quantitative values for the amount of His-NHERF fusion protein bound to each well. Specific binding is defined as the binding to wells coated with a GST-NHERF-1 fusion protein minus the binding to wells coated with GST alone on the same plate.
Pull-down Assays-For GST-NHERF-1 pull-down assays of purified fusion proteins, GST-NHERF-1 fusion proteins and GST alone were purified on glutathione-agarose beads as described above. Aliquots of the fusion protein/bead mixture (50 l) in 1.5-ml microcentrifuge tubes were blocked for 30 min with 1 ml of 3% bovine serum albumin blocking buffer (also containing 10 mM HEPES, 50 mM NaCl, and 0.1% Tween 20) . Equal concentrations of various His-tagged fusion proteins were then incubated with the beads in 1 ml of 3% bovine serum albumin blocking buffer at 4°C with end-over-end rotation for 1 h. The beads were washed four times with ice-cold 3% bovine serum albumin blocking buffer and twice with harvest buffer. The proteins were eluted from the beads with 1ϫ SDS-PAGE sample buffer, resolved via SDS-PAGE, and transferred to nitrocellulose. The His-tagged fusion proteins were detected via Western blotting with S protein-horseradish peroxidase conjugate (1:4000 dilution; Novagen), and bands were visualized via chemiluminescence as described above.
For GST, GST-NHERF-1, GST-Pin1, and GST-MAGI-WW pull-down assays of cell lysates, cells were harvested from 10-cm plates and lysed in 500 l of ice-cold lysis buffer (10 mM HEPES, 50 mM NaCl, 0.5% Triton X-100, 5 mM EDTA, and protease inhibitor mixture). The lysate was solubilized via end-over-end rotation at 4°C for 30 min and clarified via centrifugation at 14,000 rpm for 15 min. A small fraction of the supernatant was taken at this point and incubated with SDS-PAGE sample buffer to examine expression of proteins in the whole cell extract. The remaining supernatant was incubated with 50 l of GST, GST-NHERF-1, or GST-Pin1 fusion protein adsorbed onto glutathioneagarose. These incubations were carried out for 2 h with end-over-end rotation at 4°C. After five washes with 1.0 ml of lysis buffer, the pulled-down proteins were eluted from the beads with 1ϫ SDS-PAGE sample buffer, resolved by SDS-PAGE, and subjected to Western blot analysis with an anti-NHERF-1 (anti-EBP50) antibody (BD Transduction Laboratories). In some cases, the amount of NHERF-1 remaining in the lysate was also quantified using the anti-NHERF-1 antibody to assess the percentage of total cellular NHERF-1 that had been pulled down by the fusion protein.
Immunoprecipitation-Cells were harvested and lysed in 500 l of ice-cold lysis buffer. The lysate was solubilized via end-over-end rotation at 4°C for 30 min and clarified via centrifugation at 14,000 rpm for 15 min. A small fraction of the supernatant was taken at this point and incubated with SDS-PAGE sample buffer to examine expression of proteins in the whole cell extract. The remaining supernatant was incubated with 10 l of anti-Cdc2 antibody (Oncogene Research Products) and 30 l of protein A/G-agarose (Calbiochem) for 2 h with endover-end rotation at 4°C. After five washes with 1.0 ml of lysis buffer, the immunoprecipitated proteins were eluted from the beads with 1ϫ SDS-PAGE sample buffer, resolved by SDS-PAGE, and subjected to Western blot analysis with the anti-NHERF-1 (anti-EBP50) antibody.
RESULTS
To examine if the phosphorylation state of NHERF-1 might be regulated during the cell cycle, HeLa cells were synchronized and harvested at different cell cycle time points. Previous studies have shown that phosphorylation of NHERF-1 can significantly increase the apparent size of the NHERF-1 polypeptide on SDS-polyacrylamide gels (4, 22, 29 -31) . Thus, NHERF-1 phosphorylation was assessed in these initial studies via Western blotting with the anti-NHERF-1 antibody. As shown in Fig. 1A , NHERF-1 from mitosis phase cells exhibited an ϳ4-kDa increase in apparent size upon SDS-PAGE relative to NHERF-1 from cells in any other stage of the cell cycle. This mitosis phase-dependent shift in NHERF-1 mobility upon SDS-PAGE was completely blocked by treatment of mitosis phase cells with roscovitine, a selective inhibitor of cyclin-dependent kinase activity (Fig. 1B) . These findings reveal that endogenous NHERF-1 is phosphorylated by cyclin-dependent kinases during mitosis phase in HeLa cells.
Cyclin-dependent kinases typically bind to their substrates with high affinity (35) . Thus, we next examined whether we could detect a physical complex in cells between NHERF-1 and the cyclin-dependent kinase Cdc2. Cell lysates were prepared from three different cell types (HEK-293, ES2, and HeLa), and endogenous Cdc2 was immunoprecipitated from each lysate using the anti-Cdc2 antibody. Anti-NHERF-1 Western blots of the immunoprecipitates revealed robust co-immunoprecipitation of endogenous NHERF-1 with Cdc2 from all three of the cell lysates examined (Fig. 2 ). These data demonstrate that endogenous NHERF-1 and endogenous Cdc2 physically associate in a variety of cell types.
We next performed in vitro phosphorylation assays to examine whether Cdc2 might be able to directly phosphorylate NHERF-1. As shown in Fig. 3A , incubation of purified Cdc2/ cyclin B with purified His-NHERF-1 or His-NHERF-2 fusion proteins in the presence of [ 32 P]ATP resulted in specific phosphorylation of NHERF-1, but not NHERF-2. The normalized levels of the fusion proteins are shown in Fig. 3B . NHERF-1 contains two serine residues (Ser 279 and Ser 301 ) that roughly conform to the consensus motif (SPX(R/K)) for phosphorylation by Cdc2 (35, 36) . These two serines are not conserved in NHERF-2, and their relative positions within the NHERF-1 polypeptide are schematically illustrated in Fig. 3C . Mutation of Ser 279 to an amino acid that cannot be phosphorylated, either alanine or aspartate, resulted in a significant decrease in Cdc2-mediated in vitro phosphorylation of NHERF-1 (Fig.  3, A and B, third lanes) . Similarly, mutation of Ser 301 also reduced Cdc2-mediated phosphorylation of NHERF-1 (Fig. 3,  A and B, fourth lanes) . Mutation of both residues together completely abolished Cdc2-mediated phosphorylation of NHERF-1 (Fig. 3, A and B, fifth lanes) , indicating that these two serines are the primary sites at which NHERF-1 is phosphorylated by Cdc2.
In addition to preparing the NHERF-1 Ser 279 /Ser 301 mutants as purified fusion proteins, we also prepared these mutants for expression in mammalian cells. As shown in Fig. 4A , the mitosis phase-induced shift in SDS-PAGE mobility observed with wild-type NHERF-1 was completely blocked by mutation of Ser 279 and Ser 301 to alanine. This finding suggests that Ser 279 and Ser 301 are the sites of the mitosis phase-dependent NHERF-1 phosphorylation and furthermore suggests that phosphorylation of these sites induces a conformational change in NHERF-1 that alters the mobility of NHERF-1 on SDSpolyacrylamide gels. This idea is further strengthened by observations that mutation of Ser 279 and Ser 301 to aspartate, which should mimic phosphorylation of these residues, resulted in a NHERF-1 mutant that was shifted upward in apparent size on SDS-polyacrylamide gels (Fig. 4B ) in a manner similar to that observed for wild-type NHERF-1 during mitosis phase.
We next sought to understand the functional significance of NHERF-1 phosphorylation at Ser 279 and Ser 301 . To assess whether phosphorylation of these two residues might alter NHERF-1 oligomerization, GST-NHERF-1 immobilized on beads was incubated with lysates from either interphase HeLa cells or mitosis phase HeLa cells. The amount of endogenous NHERF-1 that bound to the immobilized GST-NHERF-1 was then examined via a pull-down assay (Fig. 5A ). These studies revealed that ϳ50% of endogenous NHERF-1 could be pulled down from the lysates prepared from interphase cells, but that Ͻ10% of endogenous NHERF-1 from mitosis phase cells could be pulled down. These data indicate that hyperphosphorylation of NHERF-1 in mitosis phase impairs its ability to oligomerize. Similarly, the S279D/S301D mutant of NHERF-1 expressed as a fusion protein exhibited significantly reduced oligomerization in vitro when analyzed both in plate binding assays (Fig. 5B) and in pull-down assays (Fig. 5C) . Thus, using three independent techniques, it was found that phosphorylation of NHERF-1 at Ser 279 and Ser 301 in cells or mutation of Ser 279 and Ser 301 to aspartate (to mimic phosphorylation) markedly reduces NHERF-1 oligomerization.
For several known Cdc2 substrates, it has been shown that phosphorylation by Cdc2 promotes physical association of the substrate protein with the peptidylprolyl isomerase Pin1 via the Pin1 WW domain (32, (37) (38) (39) (40) (41) (42) (43) . We therefore examined whether NHERF-1 associates with Pin1 in a phosphorylationdependent fashion. Lysates from HeLa cells in either interphase or mitosis phase were incubated with beads loaded with control GST, GST-Pin1 fusion protein, or another fusion protein (GST-MAGI-WW) that contains the two WW domains of the scaffolding protein MAGI-2/AIP1 (44). Pull-down assays followed by anti-NHERF-1 Western blotting revealed robust association of GST-Pin1 with NHERF-1 from mitosis phase lysates, but not from interphase lysates (Fig. 6) . No NHERF-1 was detectable in any of the control GST pull-down samples or in any of the GST-MAGI-WW pull-down samples. These data indicate that NHERF-1 specifically associates with Pin1, but only when NHERF-1 is hyperphosphorylated by cyclin-dependent kinases in mitosis phase.
It has recently been shown that Pin1 can, in some cases, alter the rate of dephosphorylation of its binding partners (42, 45) . We therefore examined the dephosphorylation of NHERF-1 by harvesting synchronized HeLa cells at a number of time points following mitosis phase. As shown in Fig. 7A , the SDS-PAGE mobility of NHERF-1 was reduced in a time-dependent fashion following mitosis phase. This reduction in the apparent size of NHERF-1 most likely reflects dephosphorylation of NHERF-1 by protein phosphatase-1 and/or protein phosphatase-2A since the effect could be blocked by the phosphatase inhibitors okadaic acid and calyculin A (Fig. 7B) . This dephosphorylation of NHERF-1 could be blocked also by juglone, an inhibitor of Pin1 prolyl isomerase activity (Fig. 7C ). Taken together with the GST-Pin1 pull-down experiments, these data indicate that Pin1 associates with hyperphosphorylated NHERF-1 during mitosis phase and regulates NHERF-1 dephosphorylation. The lysates were then separated on 12% SDS-polyacrylamide gels and analyzed via Western blotting with an anti-FLAG antibody. Wild-type NHERF-1 was significantly phosphorylated during mitosis, as assessed by mobility shift upon SDS-PAGE. In contrast, the S279A/S301A NHERF-1 mutant did not exhibit any mobility shift in mitosis phase. This blot is representative of three independent experiments. B, S279D/S301D NHERF-1 fusion protein mimics mitotic NHERF-1 phosphorylation. His-tagged fusion proteins corresponding to wild-type NHERF-1 and NHERF-1 mutated to aspartate at both Ser 279 and Ser 301 (S279/301D) were run on a 12% SDSpolyacrylamide gel and examined via Coomassie Blue staining. The S279D/S301D mutation induced a mobility shift in NHERF-1 similar to that observed for mitosis phase phosphorylation of cellular NHERF-1 at Ser 279 and Ser
301
. Molecular mass standards (in kilodaltons) are shown on the left.
DISCUSSION
Our findings reveal that cellular NHERF-1 is phosphorylated during mitosis phase at Ser 279 and Ser 301 by the cyclindependent kinase Cdc2. The only previously identified site of NHERF-1 phosphorylation is Ser 289 , which can be phosphorylated by several kinases in vitro, but is mainly phosphorylated by GRK6A in cells (22) . Mutation of Ser 289 to Ala reduces phosphorylation of cellular NHERF-1, but S289A NHERF-1 mutants still exhibit significant cellular phosphorylation (22, 29) . Thus, it has been widely recognized that there must be additional phosphorylation sites on NHERF-1 other than Ser 289 . The identities of these sites and the kinases that phosphorylate them have remained elusive, however. In the experiments described here, we have identified two novel NHERF-1 phosphorylation sites and a kinase (Cdc2) that efficiently phosphorylates the two identified sites both in vitro and in cells.
Phosphorylation of NHERF-1 at Ser 289 significantly enhances NHERF-1 oligomerization (28 -phosphorylated) in which the PDZ domains are less accessible for oligomerization. This idea could be most directly examined through crystallographic approaches. The crystal structure of NHERF-1 PDZ1 has recently been solved (46) , but the crystal structure of full-length NHERF-1 has yet to be described.
We observed that NHERF-1 is hyperphosphorylated during mitosis phase and then becomes dephosphorylated during interphase through the actions of protein phosphatase-1 and/or protein phosphatase-2A. Blockade of these phosphatases with okadaic acid or calyculin A maintains NHERF-1 in a hyperphosphorylated state. Interestingly, Shenolikar et al. (27) have reported that treatment of cells with okadaic acid markedly decreases NHERF-1 oligomerization. This finding is consistent FIG. 5 . NHERF-1 phosphorylation during mitosis phase inhibits NHERF-1 oligomerization. A, NHERF-1 phosphorylation during mitosis phase inhibits NHERF-1/NHERF-1 oligomerization. Lysates derived from either interphase or mitosis phase HeLa cells were incubated with glutathione-agarose beads loaded with GST or wild-type (wt) GST-NHERF-1, and the amount of NHERF-1 remaining in the supernatant was assessed following pull-down. Approximately 50% of the cellular NHERF-1 from interphase lysates was pulled down by the GST-NHERF-1 fusion protein. In contrast, Ͻ10% of the cellular NHERF-1 in the mitosis phase lysates was pulled down by GST-NHERF-1, indicating that mitosis phase NHERF-1 is markedly impaired in its ability to oligomerize. The bars and error bars represent the means Ϯ S.E. for three independent experiments, and the inset shows the data from a representative experiment. B, the S279D/S301D (S279/301D) mutation decreases NHERF-1/NHERF-1 oligomerization in a plate binding assay. The binding of wild-type His-NHERF-1 (300 nM) to wells coated with 1 g of GST, GST-NHERF-1, or GST-S279D/ S301D NHERF-1 was quantitated. The S279D/S301D mutant exhibited decreased oligomerization relative to the wild type. The data for each condition are expressed as the percent binding of that observed for wild-type His-NHERF-1 to wild-type GST-NHERF-1 on the same plate. The bars and error bars represent the means Ϯ S.E. for three independent experiments, each performed in triplicate. C, the S279D/S301D mutation decreases NHERF-1/NHERF-1 oligomerization in a pulldown assay. Equal concentrations (100 nM) of wild-type His-NHERF and His-S279D/S301D NHERF-1 were incubated with glutathione-agarose beads loaded with either GST or GST-NHERF-1. No binding of His-NHERF-1 or His-S279D/S301D NHERF-1 to control GST was detectable under these conditions. In contrast, GST-NHERF-1 beads consistently pulled down both His-NHERF-1 and His-S279D/S301D NHERF-1. However, the amount of mutant fusion protein pulled down was markedly decreased relative to the wild type. These data are representative of three independent experiments. FIG. 6. Interaction of mitosis phase NHERF-1 with Pin1. HeLa cell lysates prepared from interphase (I lanes) or mitosis phase (M lanes) cells were incubated with glutathione-agarose beads loaded with GST, GST-Pin1, or GST-MAGI-WW (a fusion protein containing the WW domains of MAGI-2). After washing, proteins associated with the beads were subjected to Western blotting with the anti-NHERF-1 antibody (A), whereas total lysates were also examined as a control (B) . No binding of NHERF-1 to control GST or GST-MAGI-WW was detectable under any condition. In contrast, the GST-Pin1 beads robustly pulled down NHERF-1 from mitosis phase lysates, but not from interphase lysates. The data shown are representative of four independent experiments.
with our observation that NHERF-1 oligomerization is impaired by phosphorylation of Ser 279 and Ser 301 . If cellular phosphorylation of Ser 279 and Ser 301 is prolonged by treatment with okadaic acid, as we have observed, the net result should be a decreased capacity of NHERF-1 for oligomerization, as Shenolikar et al. (27) have observed. Superficially, it might seem that inhibition of phosphatase activity could have mixed effects on NHERF-1 oligomerization since phosphorylation of Ser 279 and Ser 301 and phosphorylation of Ser 289 regulate oligomerization of NHERF-1 in different directions. However, Ser 289 is kept constitutively phosphorylated in most cells by a tightly associated kinase (GRK6A) and is not highly regulated by phosphatases (22) . Thus, inhibition of phosphatase activity should preferentially enhance phosphorylation of Ser 279 and Ser 301 , leading to a decrease in NHERF-1 oligomerization, as Shenolikar et al. (27) have reported.
NHERF-1 and NHERF-2 share 52% sequence identity and have many functional similarities. For example, they both regulate Na ϩ /H ϩ exchange (3, 7); they both bind to the ERM proteins (4, 5, 14, 47, 48) ; and their PDZ domains have similar binding preferences (6, 8, 10, 11, (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) . Given this multitude of similarities, it has become a point of significant interest to characterize potential functional differences between the two proteins. This work demonstrates that NHERF-1 is an excellent substrate for Cdc2, but NHERF-2 is not. There are no antibodies against NHERF-2 currently commercially available; and thus, we could not directly determine whether or not endogenous NHERF-2 exhibits hyperphosphorylation during mitosis phase as does NHERF-1. However, we did perform studies expressing hemagglutinin-tagged NHERF-2 in several different cell types, and in no case did we observe any cell cycle-dependent shift in mobility as with NHERF-1 (data not shown). Indeed, it has been reported that NHERF-2 is not phosphorylated in cells at all, under any conditions (30) . It therefore seems likely that a key functional difference between NHERF-1 and NHERF-2 is that NHERF-1 is heavily regulated in cells by phosphorylation, whereas NHERF-2 is not.
Phosphorylation of NHERF-1 at Ser 279 and Ser 301 not only decreases NHERF-1 oligomerization, but also enhances binding of NHERF-1 to the peptidylprolyl isomerase Pin1. Phosphorylation of NHERF-1 Ser 279 and Ser 301 may therefore be viewed as a "switch," enhancing association of NHERF-1 with some proteins (like Pin1) while decreasing association with other proteins (like other NHERF proteins). Furthermore, Pin1 is capable of inducing profound conformational changes in some of its binding partners due to Pin1-mediated isomerization of Ser-Pro bonds (43, 49) . Such conformational changes may lead to further alterations in protein-protein interactions, notably changes in interactions with protein phosphatases (42, 45) . Regulation of NHERF-1 interactions via phosphorylation and consequent Pin1 association is likely to have a significant impact on NHERF-1 cellular function since NHERF-1 is viewed predominantly as an adaptor protein (9) and is therefore functionally defined by the set of proteins with which it can interact. Moreover, the phosphorylation-dependent interaction of NHERF-1 with Pin1 may have consequences not only for NHERF-1 regulation, but also for regulation of Pin1. Pin1 has been found to associate with a number of other intracellular proteins (32, (37) (38) (39) (40) (41) (42) (43) 45) and is known to play a key role in the regulation of the cell cycle and apoptosis (50) . It is possible that NHERF-1 may modulate some of these actions of Pin1 in a phosphorylation-dependent fashion. What are the broader potential physiological implications of the Cdc2-NHERF-1 interaction reported here? NHERF-1 was originally identified as a cofactor necessary for hormonal regulation of NHE3, the renal Na ϩ /H ϩ exchanger (3). Interestingly, hormonal regulation of NHE3 is known to be strongly modulated during the cell cycle (51) . The molecular basis of this regulation has not been elucidated, however. Since the mitosis phase-dependent and Cdc2-mediated phosphorylation of NHERF-1 that we have observed alters NHERF-1 oligomerization and NHERF-1 association with other proteins, it might also potentially alter NHERF-1 regulation of NHE3. Furthermore, NHERF-1 has been implicated in a variety of cellular functions other than modulation of Na ϩ /H ϩ exchange (9) , and the regulation of NHERF-1 by Cdc2 may therefore have implications for the regulation of the various trafficking and signaling pathways in which NHERF-1 is involved.
In summary, we have found that NHERF-1 is hyperphosphorylated during mitosis phase and that this phosphorylation is mediated by Cdc2. We furthermore have identified two novel sites of NHERF-1 phosphorylation (Ser 279 and Ser 301 ) that conform to the optimal motif for Cdc2 phosphorylation and that mutagenesis studies have demonstrated are indeed the sites for Cdc2-mediated phosphorylation of NHERF-1. Finally, we have found that phosphorylation of NHERF-1 by Cdc2 inhibits NHERF-1 oligomerization and simultaneously promotes NHERF-1 association with the peptidylprolyl isomerase Pin1. NHERF-1 was first identified as a protein involved in the regulation of Na ϩ /H ϩ exchange by phosphorylation (3); and the alternative name for NHERF-1, ezrin-binding phosphoprotein of 50 kDa (4), reflects early recognition that NHERF-1 is highly phosphorylated in most cell types. The findings reported here contribute to the understanding of NHERF-1 regulation by phosphorylation. More specifically, these findings describe a molecular mechanism by which cellular signaling pathways involving NHERF-1 may be regulated by the cyclin-dependent kinase Cdc2 in a cell cycle-dependent fashion.
